FDA posts warning letters to drug manufacturers every week. Most follow an inspection whose observations were first listed on a Form FDA 483. We write up each letter from FDA's own published text: every finding, why plants run into it, how it is prevented, and where Atto Pharma eBMR, Atto eLogbooks and Atto QMS help.
The weekly FDA digest brings that week's letters to your inbox every Monday morning (India time), with a line on each and a link to the full analysis.
- One email a week; nothing in a week with no new letters.
- Written for QA, production, engineering and IT in pharmaceutical plants.
- Free. Unsubscribe in one click from any digest.
Subscribe